First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Factor XI Monoclonal Antibody SHR-2004 in Healthy Subjects

待确认 20 由上弦月发布于 2026/5/15 20:57:02

DOI:10.1182/blood-2023-173295
作者：Tingting Ma, B. Cao, Zuyi Weng, Yanli Dong, Shimin An, Lei Huang, Yuanxun Yang, Yan Geng, Hui Lin, Yuqi Wang, Pinhao Xie, Kai Shen, Juan Li
文献类型：期刊论文
补充材料：只需要正文

American Society of Hematology (ASH)

Abstract：Introduction: Thromboembolic disease is a major global health problem. Inhibition of coagulation factor XI (FXI) is a novel strategy for the prevention and treatment of thrombotic diseases w

应助信息

等待求助人确认

求助人未确认前，本求助不能再次应助。36小时后系统将自动确认应助成功。本求助将自动关闭。

1天前

Book学术机器人

202604030927504403986.pdf

1天前

Book学术机器人

2026/5/15 20:57:02 Book学术AI机器人已找到文献并上传

2026/5/15 20:57:02 Book学术AI机器人收到请求，开始寻找文献

2026/5/15 20:57:02 已向机器人发送请求

1天前

上弦月发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:WileyA nutrient–microalgae–Ulva prolifera biological model: Key factors and processes in the control of green tides in the Yellow Sea